CRP Predicts Biochemical but Not Clinical Remission in Ustekinumab-Treated Crohn's Disease: A Remission-Specific Whole-Blood Transcriptomic Signature
Journal of Precision Medicine and Artificial Intelligence · 09.06.2026
DOI: 10.64949/81rdwc86 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Precision Medicine and Artificial Intelligence, online erschienen am 09.06.2026. Verfasst von Simbarashe Magwenzi. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This article is a preprint and has not yet been peer-reviewed. Not for clinical use. Background and AimsClinical outcome prediction in ustekinumab-treated Crohn's disease remains a significant unmet need. C-reactive protein (CRP) is widely used as a biochemical marker of inflammation, yet its utility as a predictor of clinical remission alongside blood transcriptomics has not been formally evaluated.MethodsPredictive model training used GSE207465 (n=353, ustekinumab-treated, UNITI-2 trial; whole-blood RNA, HuGene 2.1 ST). Co-primary endpoints were CRP normalisation (serum CRP
Zitieren
APA
Magwenzi, S. (2026). CRP Predicts Biochemical but Not Clinical Remission in Ustekinumab-Treated Crohn's Disease: A Remission-Specific Whole-Blood Transcriptomic Signature. Journal of Precision Medicine and Artificial Intelligence. https://doi.org/10.64949/81rdwc86
Vancouver
Magwenzi S. CRP Predicts Biochemical but Not Clinical Remission in Ustekinumab-Treated Crohn's Disease: A Remission-Specific Whole-Blood Transcriptomic Signature. Journal of Precision Medicine and Artificial Intelligence. 2026. doi:10.64949/81rdwc86
BibTeX
@article{Magwenzi2026,
author = {Magwenzi, Simbarashe},
title = {CRP Predicts Biochemical but Not Clinical Remission in Ustekinumab-Treated Crohn's Disease: A Remission-Specific Whole-Blood Transcriptomic Signature},
journal = {Journal of Precision Medicine and Artificial Intelligence},
year = {2026},
doi = {10.64949/81rdwc86}
}
EUVIMED